Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial - Concepedia

Concepedia

Publication | Closed Access

Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial

379

Citations

23

References

2013

Year

Christopher S. Kovács, V Seshiah, Ros Swallow, Russell Jones, H. Rattunde, Hans J. Woerle, Uli C. Broedl

Diabetes Obesity and Metabolism

Abstract

Empagliflozin 10 mg and 25 mg once daily for 24 weeks as add-on to pioglitazone ± metformin reduced HbA1c, FPG and weight and were well tolerated in patients with T2DM.

References

	Year	Citations

Page 1